[go: up one dir, main page]

DK3656793T3 - Monoklonale antistoffer mod claudin-18 til cancerbehandling - Google Patents

Monoklonale antistoffer mod claudin-18 til cancerbehandling Download PDF

Info

Publication number
DK3656793T3
DK3656793T3 DK19202848.8T DK19202848T DK3656793T3 DK 3656793 T3 DK3656793 T3 DK 3656793T3 DK 19202848 T DK19202848 T DK 19202848T DK 3656793 T3 DK3656793 T3 DK 3656793T3
Authority
DK
Denmark
Prior art keywords
monoclonal antibodies
antibodies against
cancer treatment
against claudin
claudin
Prior art date
Application number
DK19202848.8T
Other languages
English (en)
Inventor
Ugur Sahin
Özlem Türeci
Dirk Usener
Stefan Fritz
Christoph Uherek
Gunda Brandenburg
Harald-Gerhard Geppert
Anja Kristina Schröder
Philippe Thiel
Original Assignee
Astellas Pharma Inc
Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc, Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh filed Critical Astellas Pharma Inc
Application granted granted Critical
Publication of DK3656793T3 publication Critical patent/DK3656793T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1063—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from stomach or intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6821—Plant heterodimeric toxins, e.g. abrin or modeccin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6821—Plant heterodimeric toxins, e.g. abrin or modeccin
    • A61K47/6823—Double chain ricin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6859—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from liver or pancreas cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Botany (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK19202848.8T 2005-11-24 2006-11-24 Monoklonale antistoffer mod claudin-18 til cancerbehandling DK3656793T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05025657A EP1790664A1 (en) 2005-11-24 2005-11-24 Monoclonal antibodies against claudin-18 for treatment of cancer
EP17192466.5A EP3312197B1 (en) 2005-11-24 2006-11-24 Monoclonal antibodies against claudin-18 for treatment of cancer

Publications (1)

Publication Number Publication Date
DK3656793T3 true DK3656793T3 (da) 2022-03-07

Family

ID=36090797

Family Applications (8)

Application Number Title Priority Date Filing Date
DK18185237.7T DK3421498T3 (da) 2005-11-24 2006-11-24 Monoklonale antistoffer mod claudin-18 til behandling af cancer
DK10011775.3T DK2311878T3 (da) 2005-11-24 2006-11-24 Monoklonale antistoffer mod Claudin-18 til behandling af kræft
DK06818817.6T DK1948693T3 (da) 2005-11-24 2006-11-24 Monoklonale antistoffer mod claudin-18 til behandling af cancer
DK10011776.1T DK2311879T3 (da) 2005-11-24 2006-11-24 Monoklonale antistoffer mod claudin-18 til behandling af cancer
DK10011772.0T DK2325210T3 (da) 2005-11-24 2006-11-24 Monoklonale antistoffer mod claudin-18 til behandling af cancer
DK17192466T DK3312197T3 (da) 2005-11-24 2006-11-24 Monoklonale antistoffer mod claudin-18 til behandling af cancer
DK19202848.8T DK3656793T3 (da) 2005-11-24 2006-11-24 Monoklonale antistoffer mod claudin-18 til cancerbehandling
DK10011773.8T DK2311877T3 (da) 2005-11-24 2006-11-24 Monoklonale antistoffer mod claudin-18 til behandling af cancer

Family Applications Before (6)

Application Number Title Priority Date Filing Date
DK18185237.7T DK3421498T3 (da) 2005-11-24 2006-11-24 Monoklonale antistoffer mod claudin-18 til behandling af cancer
DK10011775.3T DK2311878T3 (da) 2005-11-24 2006-11-24 Monoklonale antistoffer mod Claudin-18 til behandling af kræft
DK06818817.6T DK1948693T3 (da) 2005-11-24 2006-11-24 Monoklonale antistoffer mod claudin-18 til behandling af cancer
DK10011776.1T DK2311879T3 (da) 2005-11-24 2006-11-24 Monoklonale antistoffer mod claudin-18 til behandling af cancer
DK10011772.0T DK2325210T3 (da) 2005-11-24 2006-11-24 Monoklonale antistoffer mod claudin-18 til behandling af cancer
DK17192466T DK3312197T3 (da) 2005-11-24 2006-11-24 Monoklonale antistoffer mod claudin-18 til behandling af cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK10011773.8T DK2311877T3 (da) 2005-11-24 2006-11-24 Monoklonale antistoffer mod claudin-18 til behandling af cancer

Country Status (23)

Country Link
US (9) US8168427B2 (da)
EP (11) EP1790664A1 (da)
JP (4) JP5933157B2 (da)
KR (7) KR101669631B1 (da)
CN (3) CN103509114B (da)
AU (1) AU2006316767B9 (da)
BR (1) BRPI0618920B8 (da)
CA (3) CA2628126C (da)
CY (8) CY1114050T1 (da)
DK (8) DK3421498T3 (da)
ES (9) ES2642688T3 (da)
HR (8) HRP20220246T3 (da)
HU (7) HUE058777T2 (da)
LT (5) LT3312197T (da)
ME (1) ME03608B (da)
MX (4) MX377450B (da)
PL (8) PL3312197T3 (da)
PT (8) PT2311878E (da)
RS (8) RS54468B1 (da)
RU (1) RU2445319C2 (da)
SG (2) SG10201405134WA (da)
SI (8) SI1948693T1 (da)
WO (1) WO2007059997A1 (da)

Families Citing this family (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10254601A1 (de) * 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
WO2005121338A1 (ja) * 2004-06-07 2005-12-22 Kyowa Hakko Kogyo Co., Ltd. 抗ｐｅｒｐ抗体
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
CA2632419A1 (en) * 2005-12-06 2007-06-14 Kyowa Hakko Kogyo Co., Ltd. Genetically recombinant anti-perp antibody
EP1997832A1 (en) * 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoclonal antibodies against Claudin-18 for treatment of cancer
US8846036B2 (en) * 2007-10-19 2014-09-30 Abbott Laboratories Antibodies that bind to mammalian NGAL and uses thereof
US20090124022A1 (en) * 2007-10-19 2009-05-14 Abbott Laboratories Antibodies that bind to mammalian ngal and uses thereof
US20090123946A1 (en) * 2007-10-19 2009-05-14 Abbott Laboratories Immunoassays and kits for the detection of ngal
HRP20231525T1 (hr) 2009-02-20 2024-03-15 Astellas Pharma Inc. Postupci i pripravci za dijagnozu i liječenje raka
HUE035516T2 (en) * 2009-11-11 2018-05-28 Ganymed Pharmaceuticals Gmbh Antibodies specific to Claulin-6 (CLDN6)
WO2011063523A1 (en) * 2009-11-24 2011-06-03 Alethia Biotherapeutics Inc. Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
SG10201501342UA (en) * 2010-02-24 2015-04-29 Immunogen Inc Folate receptor 1 antibodies and immunoconjugates and uses thereof
EP2404936A1 (en) * 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
ES2632486T3 (es) * 2010-10-18 2017-09-13 Mediapharma S.R.L. Anticuerpo de unión a ErbB3
DK2663579T3 (da) 2011-01-14 2017-07-31 Univ California Terapeutiske antistoffer mod ror-1-protein og fremgangsmåder til anvendelse deraf
AR085091A1 (es) 2011-01-26 2013-09-11 Kolltan Pharmaceuticals Inc Anticuerpos anti-kit y sus usos
WO2012109282A2 (en) * 2011-02-07 2012-08-16 Agamin Pharmaceuticals, Llc Methods and systems for treating or preventing pregnancy-related hypertensive disorders
US8722044B2 (en) 2011-03-15 2014-05-13 Janssen Biotech, Inc. Human tissue factor antibody and uses thereof
SI2694106T1 (en) 2011-04-01 2018-04-30 Immunogen, Inc. Methods for increasing the effectiveness of treatment with FOLR1 receptor cancer
JP6276176B2 (ja) 2011-05-13 2018-02-07 ガニメド ファーマシューティカルズ ゲーエムベーハー 癌の治療のための抗体
BR112014015323B1 (pt) 2011-12-20 2022-09-27 Janssen Biotech, Inc Anticorpos anti-phf-tau, seu método de produção, polinucleotídeo isolado que codifica uma vh de anticorpo, e vetor
CA2862739A1 (en) 2012-02-22 2013-08-29 Alethia Biotherapeutics Inc. Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer
WO2013167153A1 (en) * 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
WO2013174404A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
EP4556070A3 (en) 2012-05-23 2025-08-27 Astellas Pharma, Inc. Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
DK3725810T3 (da) 2012-05-23 2022-07-25 Astellas Pharma Inc Kombinationterapi, der involverer antistoffer mod claudin 18.2 til behandling af cancer
WO2013174403A1 (en) * 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
SG11201500489YA (en) 2012-07-25 2015-02-27 Kolltan Pharmaceuticals Inc Anti-kit antibodies and uses thereof
US9200073B2 (en) 2012-08-31 2015-12-01 Immunogen, Inc. Diagnostic assays and kits for detection of folate receptor 1
UA128182C2 (uk) 2012-11-13 2024-05-01 Біонтех Аґ Агенти для лікування експресуючих клаудин ракових захворювань
EP3766903A3 (en) * 2012-11-13 2021-02-17 BioNTech SE Bispecific anti claudin xcd3 antibodies for treatment of claudin expressing cancer diseases
EP4154907A1 (en) 2012-12-18 2023-03-29 Icahn School of Medicine at Mount Sinai Influenza virus vaccines and uses thereof
SMT202200458T1 (it) * 2013-02-20 2023-01-13 Astellas Pharma Inc Terapia combinata con anticorpi contro la claudina 18.2 per il trattamento del cancro
WO2014127785A1 (en) * 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014159960A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
WO2014159531A1 (en) * 2013-03-14 2014-10-02 The Board Of Regents Of The University Of Texas System Monoclonal antibodies targeting epcam for detection of prostate cancer lymph node metastases
WO2014146672A1 (en) * 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
EP2976360B1 (en) * 2013-03-18 2019-11-27 Astellas Pharma Inc. Therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2015014376A1 (en) 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
CA3222465A1 (en) 2013-08-30 2015-03-05 Immunogen, Inc. Antibodies and assays for detection of folate receptor 1
RU2016122041A (ru) 2013-11-06 2017-12-11 ЭББВИ СТЕМСЕНТРКС ЭлЭлСи Новые анти-клаудин антитела и способы их применения
CN106659782B (zh) 2014-05-23 2021-11-09 塞尔德克斯医疗公司 一种用于嗜酸性粒细胞或肥大细胞相关病症治疗的抗体
EP3166616B1 (en) * 2014-07-10 2021-04-07 Biothera, Inc. Beta-glucan in combination with anti-cancer agents affecting the tumor microenvironment
CN120137056A (zh) 2014-07-17 2025-06-13 恺兴生命科技(上海)有限公司 靶向cld18a2的t淋巴细胞及其制备方法和应用
JP2018504412A (ja) 2015-01-23 2018-02-15 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルスワクチン接種レジメン
WO2016180468A1 (en) * 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Claudin-18.2-specific immunoreceptors and t cell epitopes
SG10201908685QA (en) 2015-06-22 2019-10-30 Bayer Pharma AG Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups
CN107921146A (zh) * 2015-06-23 2018-04-17 拜耳医药股份有限公司 纺锤体驱动蛋白(ksp)抑制剂与抗‑cd123的抗体的抗体药物缀合物(adc)
KR20180041229A (ko) * 2015-08-25 2018-04-23 유에이비 리서치 파운데이션 줄기 세포 이식을 위한 방법
CN116440279A (zh) 2015-09-17 2023-07-18 伊缪诺金公司 包含抗folr1免疫缀合物的治疗组合
CA3027445A1 (en) 2016-06-15 2017-12-21 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies
WO2017218624A1 (en) 2016-06-15 2017-12-21 Icahn School Of Medicine At Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
WO2017218691A1 (en) * 2016-06-16 2017-12-21 The Board Of Trustees Of The Leland Stanford Junior University Humanized and chimeric monoclonal antibodies to cd81
WO2018006882A1 (zh) * 2016-07-08 2018-01-11 科济生物医药（上海）有限公司 抗密蛋白18a2的抗体及其应用
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
WO2018114804A1 (de) 2016-12-21 2018-06-28 Bayer Pharma Aktiengesellschaft Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren
MX2019007641A (es) 2016-12-21 2019-09-09 Bayer Pharma AG Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente.
JOP20180021A1 (ar) 2017-03-16 2019-01-30 Janssen Biotech Inc الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها
US11254733B2 (en) 2017-04-07 2022-02-22 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof
TW201946654A (zh) 2018-03-05 2019-12-16 比利時商健生藥品公司 抗ＰＨＦ－Ｔａｕ抗體及其用途
JP2021514662A (ja) * 2018-03-08 2021-06-17 フェインズ セラピューティクス，インコーポレーテッド 抗ｔｉｐ−１抗体及びその使用
BR112020015479A2 (pt) 2018-03-08 2020-12-08 Phanes Therapeutics, Inc. Anticorpos anticlaudina 18.2 e usos dos mesmos
CN111989344A (zh) 2018-03-09 2020-11-24 科济生物医药（上海）有限公司 用于治疗肿瘤的方法和组合物
KR102340989B1 (ko) 2018-03-28 2021-12-20 에이비온 주식회사 클라우딘 3의 ecl-2에 특이적으로 결합하는 항체, 이의 단편 및 이들의 용도
CN108517315B (zh) * 2018-03-30 2019-06-04 四川迈克生物新材料技术有限公司 抗人IgM单克隆抗体、其杂交瘤细胞株及应用
CN116178555B (zh) 2018-05-18 2025-09-09 礼新医药科技(上海)有限公司 抗密蛋白18.2抗体及其用途
EP3810634A4 (en) 2018-06-21 2022-07-27 Icahn School of Medicine at Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
WO2020018852A2 (en) * 2018-07-18 2020-01-23 Askgene Pharma Inc. Novel antibodies and methods for making and using the same
EP3827021A4 (en) * 2018-07-23 2022-08-03 Boehringer Ingelheim Pharmaceuticals, Inc. ANTIBODIES DIRECTED TO A NON-CLASSIC HLA-I/NEOANTIGEN COMPLEX AND THEIR USE
CA3110593A1 (en) * 2018-08-27 2020-03-05 Nanjing Sanhome Pharmaceutical Co., Ltd. Anti-claudin18.2 antibody and use thereof
KR102775767B1 (ko) 2018-10-22 2025-03-07 상하이 젠베이스 바이오테크놀로지 씨오., 엘티디. 항-cldn18.2 항체 및 이의 용도
EP3891183A4 (en) * 2018-12-07 2022-08-31 Zlip Holding Limited ANTI-CLAUDIN ANTIBODIES AND USES THEREOF
CN113166246B (zh) 2018-12-28 2024-10-18 四川科伦博泰生物医药股份有限公司 一种抗体及其用途
BR112021012608A2 (pt) 2018-12-28 2021-09-08 Nanjing GenScript Biotech Co., Ltd. Porção de ligação que se liga especificamente à claudina18.2, receptor de antígeno quimérico, ácido nucleico, célula imune manipulada, composição farmacêutica, e, método de tratamento de um tumor ou câncer que expressa claudina18.2
US11447551B2 (en) 2018-12-28 2022-09-20 Sparx Bioscience Limited Binding molecules specific for claudin 18.2, compositions and methods thereof, for the treatment of cancer and other diseases
CN111434692B (zh) 2019-01-15 2021-12-31 浙江道尔生物科技有限公司 抗cld18a2纳米抗体及其应用
CN109762067B (zh) * 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途
US11407828B2 (en) 2019-02-01 2022-08-09 Novarock Biotherapeutics, Ltd. Anti-CLauDiN 18 antibodies and methods of use thereof
US20220153873A1 (en) * 2019-04-24 2022-05-19 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
KR20220017892A (ko) 2019-05-08 2022-02-14 얀센 바이오테크 인코포레이티드 T세포 매개 면역의 조절을 위한 물질 및 방법
CN111944048B (zh) * 2019-05-16 2023-10-03 启愈生物技术(上海)有限公司 抗cldn抗体及其药物组合物和检测方法
AU2020273695B2 (en) 2019-05-16 2024-10-31 Qilu Pharmaceutical Co., Ltd. Antibody against claudin 18A2 and use thereof
CN114206935B (zh) * 2019-05-24 2024-01-12 三优生物医药(上海)有限公司 新型cldn18.2结合分子
US20220306765A1 (en) * 2019-08-20 2022-09-29 Suzhou Transcenta Therapeutics Co., Ltd. Novel anti-cldn18.2 antibodies
CN119019558A (zh) 2019-08-22 2024-11-26 浙江道尔生物科技有限公司 抗pd-l1纳米抗体
CN112574307B (zh) * 2019-09-29 2023-11-28 迈威(上海)生物科技股份有限公司 抗人Claudin18.2抗体及其应用
CN112707965A (zh) * 2019-09-30 2021-04-27 和铂医药(苏州)有限公司 靶向cldn18.2的抗体及其制备方法和应用
MX2022005452A (es) 2019-11-05 2022-07-27 Lanova Medicines Ltd Conjugados farmaco-anticuerpo dirigidos a la claudina 18.2.
AU2020398045A1 (en) 2019-12-06 2022-06-09 Sotio Biotech A.S. Humanized CLDN18.2 antibodies
PH12022551398A1 (en) * 2019-12-13 2023-10-09 Alector Llc Anti-mertk antibodies and methods of use thereof
BR112022012327A2 (pt) * 2019-12-23 2022-10-18 Sotio Biotech A S Anticorpos ou fragmentos dos mesmos, ácido nucleico, vetor e célula hospedeira
CN118440204A (zh) * 2019-12-27 2024-08-06 凯奥目生物科学株式会社 抗cdcp1抗体
US12486331B2 (en) 2020-01-31 2025-12-02 Gensun Biopharma Inc. Bispecific T cell engagers
EP4110820A4 (en) * 2020-02-25 2024-03-27 Gensun Biopharma Inc. TRISPECIFIC T CELL CONTACTING AGENTS
WO2021173896A1 (en) * 2020-02-27 2021-09-02 Janssen Biotech, Inc. Materials and methods for modulating an immune response
CA3174588A1 (en) 2020-03-30 2021-10-07 BioNTech SE Rna compositions targeting claudin-18.2
CN113493515B (zh) * 2020-04-02 2023-03-28 广东菲鹏制药股份有限公司 抗cldn18a2的抗体以及治疗肿瘤的药物
JP7407973B2 (ja) * 2020-05-15 2024-01-04 シチュアン ケルン－バイオテック バイオファーマシューティカル カンパニー リミテッド 抗体薬物複合体、その調製方法、およびその使用
WO2021238831A1 (en) * 2020-05-25 2021-12-02 Mabspace Biosciences (Suzhou) Co., Limited Anti-cldn18.2 antibodies and diagnostic uses thereof
WO2021239026A1 (zh) * 2020-05-29 2021-12-02 杭州邦顺制药有限公司 针对Claudin18.2的抗体及其用途
US10981997B1 (en) 2020-06-01 2021-04-20 Abexxa Biologics, Inc. Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
US10981996B1 (en) 2020-06-01 2021-04-20 Abexxa Biologics, Inc. Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
US11976120B2 (en) 2020-06-01 2024-05-07 Boehringer Ingelheim International Gmbh Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
CN113754778A (zh) * 2020-06-05 2021-12-07 上海交通大学 靶向cldn18.2的嵌合抗原受体及其用途
CN111777681B (zh) * 2020-07-06 2022-10-11 康诺亚生物医药科技（成都）有限公司 一种结合紧密连接蛋白-18.2的抗体及其用途
CN113929780A (zh) * 2020-07-13 2022-01-14 北京凯因科技股份有限公司 一种结合密蛋白的用于治疗癌症的人源化抗体
JP7726978B2 (ja) 2020-07-13 2025-08-20 上海君▲実▼生物医▲薬▼科技股▲分▼有限公司 抗ｃｌｄｎ－１８．２抗体及びその用途
CN114222761B (zh) * 2020-07-14 2024-02-20 浙江道尔生物科技有限公司 一种抗cld18a2的单域抗体
CA3194771A1 (en) 2020-09-16 2022-03-24 Amgen Inc. Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer
CN114316046B (zh) * 2020-09-29 2024-08-09 北京凯因科技股份有限公司 一种稳定的抗体组合物
TW202233674A (zh) 2020-10-28 2022-09-01 美商健生生物科技公司 用於調節δγ鏈介導之免疫的組成物及方法
EP4240415A1 (en) 2020-11-08 2023-09-13 Seagen Inc. Combination-therapy antibody drug conjugate with immune cell inhibitor
CN112480248B (zh) 2020-11-24 2023-05-05 三优生物医药(上海)有限公司 与cld18a2特异性结合的分子
WO2022122709A1 (en) 2020-12-07 2022-06-16 Sotio Biotech A.S. Antibody-drug conjugates based on humanized cldn18.2 antibodies
AU2021405049A1 (en) 2020-12-23 2023-06-22 Sotio Biotech A.S. Tumor-specific claudin 18.2 antibody-drug conjugates
EP4273167A4 (en) 2020-12-30 2025-03-26 Bio-Thera Solutions, Ltd. ANTI-CLDN18.2 ANTIBODIES AND PRODUCTION METHOD AND USE THEREOF
CA3211403A1 (en) * 2021-02-19 2022-08-25 Suzhou Transcenta Therapeutics Co., Ltd. Anti-cldn18.2 antibody conjugates
CN117042806A (zh) * 2021-03-08 2023-11-10 启德医药科技（苏州）有限公司 抗体-免疫激动剂缀合物及其应用
CN117083299A (zh) 2021-04-02 2023-11-17 原启生物科技(上海)有限责任公司 Cldn18.2抗原结合蛋白及其用途
WO2022226079A1 (en) * 2021-04-20 2022-10-27 Inbios International, Inc. Neutralizing antibodies against sars-cov-2
AU2022287071A1 (en) * 2021-05-31 2024-01-04 Shijiazhuang Yiling Pharmaceutical Co., Ltd. Monoclonal antibodies against cldn18.2 and fc-engineered versions thereof
WO2022253284A1 (zh) 2021-06-02 2022-12-08 百奥泰生物制药股份有限公司 药物偶联物及其用途
WO2022262959A1 (en) 2021-06-15 2022-12-22 Astellas Pharma Europe Bv Bispecific binding agents binding to cldn18.2 and cd3
EP4355784A1 (en) 2021-06-15 2024-04-24 Xencor, Inc. Heterodimeric antibodies that bind claudin18.2 and cd3
CA3225815A1 (en) 2021-08-13 2023-02-16 Cytune Pharma Il-2/il-15rbetagamma agonist combination with antibody-drug conjugates for treating cancer
AU2022350588A1 (en) 2021-09-27 2024-05-02 Evopoint Biosciences Co., Ltd. Antibody, antibody-drug conjugate thereof and use thereof
CN116102649A (zh) * 2021-11-11 2023-05-12 上海生物制品研究所有限责任公司 抗cldn18.2单克隆抗体及其应用
KR102809807B1 (ko) * 2021-12-21 2025-05-16 한림대학교 산학협력단 항-cldn18.2를 포함하는 키메릭 항원 수용체를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 및 이의 제조 방법
EP4482859A1 (en) 2022-02-27 2025-01-01 Boehringer Ingelheim International GmbH Bispecific antibodies against cd277 and a tumor-antigen
JP2025537044A (ja) 2022-09-30 2025-11-13 シャンハイ ドーァ ノボ ファーマテック カンパニー，リミティド ベンザゼピン誘導体、それを含む複合体およびその応用
JP2025534447A (ja) 2022-10-06 2025-10-15 バイオエヌテック エスエー クローディン１８．２を標的とするｒｎａ組成物
WO2024074211A1 (en) 2022-10-06 2024-04-11 BioNTech SE Rna compositions targeting claudin-18.2
CN115819586B (zh) * 2022-10-13 2023-10-31 珠海市丽珠单抗生物技术有限公司 抗人SIRPα单克隆抗体及其用途
TW202434307A (zh) 2023-01-18 2024-09-01 大陸商泰勵生物科技（上海）有限公司 抗體偶聯藥物及其用途
CN119306830B (zh) * 2023-07-11 2025-06-20 东莞市朋志生物科技有限公司 抗皮质醇抗体、检测皮质醇的试剂和试剂盒

Family Cites Families (205)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3044382A (en) 1957-12-14 1962-07-17 Compur Werk Friedrich Deckel Photographic shutter
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4954617A (en) 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
DE3853515T3 (de) 1987-05-21 2005-08-25 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung.
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US6020145A (en) * 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
JPH05504476A (ja) 1989-12-27 1993-07-15 アメリカ合衆国 ヒト胃癌検出用診断プローブ
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
GB9019812D0 (en) 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
GB9223377D0 (en) 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
US5589579A (en) 1994-07-19 1996-12-31 Cytoclonal Pharmaceutics, Inc. Gene sequence and probe for a marker of non-small cell lung carinoma
WO2000075316A1 (en) 1999-06-02 2000-12-14 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5677139A (en) 1995-04-21 1997-10-14 President And Fellows Of Harvard College In vitro differentiation of CD34+ progenitor cells into T lymphocytes
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
KR19990077146A (ko) 1996-01-11 1999-10-25 길리스 스티브 유방암의 치료 및 진단용 조성물 및 방법
WO2000075327A1 (en) 1999-06-02 2000-12-14 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
WO2001049715A2 (en) 2000-01-06 2001-07-12 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US7411051B2 (en) 1997-03-07 2008-08-12 Human Genome Sciences, Inc. Antibodies to HDPPA04 polypeptide
US20070224663A1 (en) 1997-03-07 2007-09-27 Human Genome Sciences, Inc. Human Secreted Proteins
US7368531B2 (en) 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
WO2000056889A2 (en) 1999-03-23 2000-09-28 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030022298A1 (en) 1997-09-15 2003-01-30 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030073129A1 (en) 1998-09-01 2003-04-17 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20020127584A1 (en) 1997-09-18 2002-09-12 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20050196832A1 (en) 1997-09-18 2005-09-08 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030008352A1 (en) 1997-09-18 2003-01-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030166107A1 (en) 1997-09-18 2003-09-04 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030027272A1 (en) 1997-09-18 2003-02-06 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030166104A1 (en) 1997-09-18 2003-09-04 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7160985B2 (en) 1997-10-29 2007-01-09 Genentech, Inc. Pro180 polypeptide
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US20030040471A1 (en) 1998-04-29 2003-02-27 Watson James D. Compositions isolated from skin cells and methods for their use
US20030022835A1 (en) 1998-04-29 2003-01-30 Genesis Research And Development Corporation Limited Compositions isolated from skin cells and methods for their use
JP3428441B2 (ja) 1998-05-15 2003-07-22 エーザイ株式会社 タイトジャンクション構成膜蛋白質クローディンファミリー
US7351543B2 (en) 1998-06-02 2008-04-01 Genentech, Inc. Antibodies to a polypeptide encoded by a nucleic acid underexpressed in melanoma
US7319008B2 (en) 1998-06-02 2008-01-15 Genentech, Inc. Nucleic acid underexpressed in melanoma
JP2002517222A (ja) 1998-06-11 2002-06-18 スミスクライン ビーチャム コーポレーション Ｇｐｒ３５ａ受容体
US7339033B2 (en) 1998-06-26 2008-03-04 Genentech, Inc. Pro1481
EP1104486A4 (en) 1998-08-04 2002-07-17 Diadexus Llc NEW METHOD FOR DIAGNOSIS, FOLLOW-UP, AND IMAGE OF LUNG CANCER
US20050181478A1 (en) 1998-09-01 2005-08-18 Baker Kevin P. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7488796B2 (en) 1998-09-01 2009-02-10 Genentech, Inc. PRO1269 polypeptides
NZ510464A (en) 1998-09-01 2004-05-28 Genentech Inc Further pro polypeptides and sequences thereof
US20030082626A1 (en) 1998-09-01 2003-05-01 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7538086B2 (en) 1998-09-01 2009-05-26 Genentech, Inc. PRO1303 polypeptides
JP2002524103A (ja) 1998-09-16 2002-08-06 ザイモジェネティクス，インコーポレイティド 胃ポリペプチドｚｓｉｇ２８
MXPA01002592A (es) 1998-09-16 2004-06-07 Genentech Inc Polipeptidos de transmembrana y secretados y acidos nucleicos que codifican los mismos.
EP1119620A2 (en) 1998-10-06 2001-08-01 Curagen Corporation Polynucleotides coding for secreted polypeptides. some having similarity to syncollin or claudin or cytokine. their therapeutic uses
US7399834B2 (en) 1998-10-07 2008-07-15 Genentech, Inc. Anti-PRO1558 antibodies
EP1080209A2 (en) 1998-10-21 2001-03-07 Arch Development Corporation Methods of treatment of type 2 diabetes
US7026449B2 (en) 1999-01-05 2006-04-11 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7507404B2 (en) 1999-03-08 2009-03-24 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU768694B2 (en) 1999-03-08 2004-01-08 Genentech Inc. Promotion or inhibition of angiogenesis and cardiovascularization
US7109292B2 (en) 1999-03-08 2006-09-19 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU2883600A (en) 1999-03-08 2000-09-28 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP2004507202A (ja) 1999-03-31 2004-03-11 キュラジェン　コーポレイション ポリペプチドをコードするオープンリーディングフレームを含む核酸；「ｏｒｆｘ」
US20080286821A1 (en) 1999-05-14 2008-11-20 Eaton Dan L Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP2004522402A (ja) 1999-06-02 2004-07-29 ジェネンテック・インコーポレーテッド 同一のものをコードする分泌及び膜貫通ポリペプチドと核酸
CA2373915A1 (en) 1999-06-02 2000-12-07 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
CA2372511C (en) 1999-06-15 2011-11-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU2883700A (en) 1999-06-23 2001-01-09 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU2883900A (en) 1999-07-07 2001-01-30 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP4944324B2 (ja) * 1999-07-13 2012-05-30 ボルダー バイオテクノロジー， インコーポレイテッド 免疫グロブリン融合タンパク質
EP1208202A2 (en) 1999-09-01 2002-05-29 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU1205901A (en) 1999-10-14 2001-04-23 Board Of Trustees Of The University Of Arkansas, The Tumor antigen derived gene-16 (tadg-16): a novel extracellular serine protease and uses thereof
EP1686134A3 (en) 1999-12-01 2006-08-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6380362B1 (en) 1999-12-23 2002-04-30 Genesis Research & Development Corporation Ltd. Polynucleotides, polypeptides expressed by the polynucleotides and methods for their use
WO2001055326A2 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US20040018969A1 (en) 2000-01-31 2004-01-29 Rosen Craig A. Nucleic acids, proteins, and antibodies
CA2396719A1 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. 22 human secreted proteins
WO2001055343A1 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
CA2401070A1 (en) 2000-02-22 2001-08-30 Corixa Corporation Compositions and methods for diagnosis and therapy of malignant mesothelioma
AU6802801A (en) 2000-03-01 2001-09-24 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU4592601A (en) 2000-03-21 2001-10-03 Millennium Predictive Medicine Novel genes, compositions, kits, and method for identification, assessment, prevention, and therapy of ovarian cancer
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
CA2405550A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
WO2001090357A1 (en) 2000-05-24 2001-11-29 Genesis Research & Development Corporation Limited Compositions isolated from skin cells and methods for their use
JP2004513878A (ja) * 2000-06-23 2004-05-13 マキシジェン，　インコーポレイテッド 新規同時刺激分子
AU2001271589A1 (en) 2000-06-30 2002-01-14 Zymogenetics Inc. Mammalian secreted proteins
CA2634294A1 (en) 2000-08-03 2002-02-14 Therapeutic Human Polyclonals, Inc. Production of humanized antibodies in transgenic animals
MXPA03001468A (es) 2000-08-15 2004-05-04 Immunex Corp Polipeptidos de claudia.
EP1309679A2 (en) 2000-08-16 2003-05-14 Chiron Corporation Human genes and gene expression products
US20030017468A1 (en) 2000-08-28 2003-01-23 Sei-Yu Chen Compositions and methods relating to lung specific genes
EP2298789B1 (en) 2000-09-08 2012-03-14 Schering Corporation Mammalian genes; related reagents and methods
JP2004526411A (ja) 2000-09-18 2004-09-02 トマス・ジエフアーソン・ユニバーシテイ 胃および食道癌細胞を同定および標的とするための組成物および方法
DK1354034T3 (da) 2000-11-30 2008-03-25 Medarex Inc Transgene transchromosomale gnavere til fremstilling af humane antistoffer
WO2002061087A2 (en) 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides
WO2002068579A2 (en) 2001-01-10 2002-09-06 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
EP1368499A2 (en) 2001-01-29 2003-12-10 Phase-1 Molecular Toxicology Inc. Rat toxicologically relevant genes and uses thereof
CN1516706A (zh) 2001-02-26 2004-07-28 阿伦纳药品公司 人g蛋白偶联受体的内源性和非内源性形式
US20030152939A1 (en) 2001-04-09 2003-08-14 Glennda Smithson Novel secreted proteins and polynucleotides encoding them
US20060084794A1 (en) 2001-04-12 2006-04-20 Human Genome Sciences, Inc. Albumin fusion proteins
JP2003000249A (ja) 2001-05-10 2003-01-07 Daiichi Fine Chemical Co Ltd クローディンによるＭＴ−ＭＭＰｓを介したｐｒｏＭＭＰ−２活性化
CA2449042A1 (en) 2001-05-30 2002-12-27 Biomedical Center In silico screening for phenotype-associated expressed sequences
EP1493028A4 (en) 2001-07-06 2006-06-14 Genentech Inc PHAGEN DISPLAY PRESENTED LIGANDS OF THE PDZ DOMAIN
AU2002321903A1 (en) 2001-08-03 2003-02-24 Arbor Vita Corporation Molecular interactions in cells
WO2004045535A2 (en) 2002-11-14 2004-06-03 Arbor Vita Corporation Molecular interactions in neurons
US6551893B1 (en) 2001-11-27 2003-04-22 Micron Technology, Inc. Atomic layer deposition of capacitor dielectric
US7202335B2 (en) 2001-12-06 2007-04-10 Genentech, Inc. PRO300 polypeptides
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
CA2379661A1 (en) 2002-03-28 2003-09-28 Kursad Turksen Paracellular drug delivery system
AU2003240495A1 (en) 2002-06-04 2003-12-19 Incyte Corporation Diagnostics markers for lung cancer
KR101228124B1 (ko) * 2002-06-14 2013-01-31 이뮤노메딕스, 인코오포레이티드 단클론 항체 ｐａｍ4 및 췌장암의 진단 및 치료를 위한이들의 용도
CA2499816C (en) * 2002-09-27 2013-07-30 Xencor, Inc. Optimized fc variants and methods for their generation
WO2004035607A2 (en) 2002-10-17 2004-04-29 Genmab A/S Human monoclonal antibodies against cd20
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
EP1430902A1 (en) 2002-12-20 2004-06-23 Mondobiotech Laboratories Anstalt Pharmaceutical composition of interferon gamma with molecular diagnostics for the improved treatment of asthma bronchiale
EP1587540B1 (en) 2003-01-09 2021-09-15 MacroGenics, Inc. IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
US20050181375A1 (en) 2003-01-10 2005-08-18 Natasha Aziz Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer
KR20060031809A (ko) 2003-06-09 2006-04-13 더 리젠츠 오브 더 유니버시티 오브 미시간 암 치료 및 진단용 조성물 및 방법
JP2007507243A (ja) 2003-10-03 2007-03-29 バイエル・フアーマシユーチカルズ・コーポレーシヨン 遺伝子発現プロファイルおよび使用方法
DE10354601B3 (de) 2003-11-21 2005-06-23 Chiropro Gmbh Gelenkprothese für Fingerglieder
WO2005052182A2 (en) 2003-11-26 2005-06-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem A method of analyzing plasma membrane protein content of cells
US7858322B2 (en) 2003-12-23 2010-12-28 Nono, Inc. Method of determining inhibition of binding to TRPM7 protein
WO2005076939A2 (en) 2004-02-09 2005-08-25 University Of Kentucky Research Foundation Assay and method for diagnosing and treating alzheimer’s disease
EP1732582A2 (en) 2004-02-26 2006-12-20 Ohio University Diagnosis of hyperinsulinemia and type ii diabetes and protection against same based on genes differentially expressed in muscle cells
AR048098A1 (es) * 2004-03-15 2006-03-29 Wyeth Corp Conjugados de caliqueamicina
US20050255041A1 (en) 2004-05-13 2005-11-17 Arius Research, Inc. Cancerous disease modifying antibodies
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
WO2005114221A2 (en) 2004-05-21 2005-12-01 The Institute For Systems Biology Compositions and methods for quantification of serum glycoproteins
WO2006023121A1 (en) 2004-07-27 2006-03-02 Ohio University Diagnosis of hyperinsulinemia and type ii diabetes and protection against same based on genes differentially expressed in white adipose tissue (13)
DE102004042822A1 (de) 2004-08-31 2006-03-16 Technische Universität Dresden Verbindungen und Methoden zur Behandlung, Diagnose und Prognose bei Pankreaserkrankungen
FR2876705B1 (fr) 2004-10-19 2008-12-12 Biomerieux Sa Procede pour le diagnostic d'une intolerance a l'aspirine
US20070072175A1 (en) 2005-05-13 2007-03-29 Biogen Idec Ma Inc. Nucleotide array containing polynucleotide probes complementary to, or fragments of, cynomolgus monkey genes and the use thereof
WO2007018843A2 (en) 2005-07-01 2007-02-15 Arbor Vita Corporation Methods and compositions for diagnosis and treatment of influenza
ZA200800970B (en) 2005-08-15 2009-10-28 Genentech Inc Gene disruptions, compositions and methods relating thereto
WO2007027867A2 (en) 2005-08-31 2007-03-08 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
JP2009508493A (ja) 2005-09-19 2009-03-05 ベリデックス・エルエルシー すい臓がんを診断するための方法
CA2625403A1 (en) 2005-10-17 2007-04-26 Institute For System Biology Tissue-and serum-derived glycoproteins and methods of their use
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
KR20080106946A (ko) 2006-03-29 2008-12-09 제넨테크, 인크. 종양의 진단 및 치료
WO2008013954A2 (en) 2006-07-27 2008-01-31 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
JP5244103B2 (ja) 2006-08-09 2013-07-24 ホームステッド クリニカル コーポレイション 器官特異的蛋白質およびその使用方法
WO2008021115A2 (en) 2006-08-14 2008-02-21 The Brigham And Women's Hospital, Inc. Diagnostic tests using gene expression ratios
RU2009114745A (ru) 2006-09-19 2010-10-27 Новартис АГ (CH) Биомаркеры, предназначенные для выявления направленной модуляции, эффективности ингибиторов raf, применения с целью диагностики и/или прогнозирования
WO2008043561A2 (en) 2006-10-11 2008-04-17 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Influenza targets
EP2097538A4 (en) 2006-12-07 2011-11-30 Switchgear Genomics TRANSCRIPTION REAGULATION ELEMENTS OF BIOLOGICAL PATHS, TOOLS AND METHODS
AU2007333106A1 (en) 2006-12-08 2008-06-19 Asuragen, Inc. miR-20 regulated genes and pathways as targets for therapeutic intervention
BRPI0807227A2 (pt) 2007-02-01 2019-01-22 Veridex Llc métodos e materiais para identificação da origem de um carcinoma de origem primária desconhecida
EP2145902A3 (en) 2007-04-19 2010-09-29 Peter Hornbeck Tyrosine phosphorylation sites and antibodies specific for them
EP1997832A1 (en) 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoclonal antibodies against Claudin-18 for treatment of cancer
WO2008154333A2 (en) 2007-06-08 2008-12-18 Asuragen, Inc. Mir-34 regulated genes and pathways as targets for therapeutic intervention
WO2008152822A1 (ja) 2007-06-15 2008-12-18 Medinet Co., Ltd. 医薬
US20100292303A1 (en) 2007-07-20 2010-11-18 Birrer Michael J Gene expression profile for predicting ovarian cancer patient survival
WO2009035497A2 (en) 2007-08-08 2009-03-19 Savidge Tor C Disease related cysteine modifications and uses thereof
EP2036987A1 (en) 2007-09-17 2009-03-18 Siemens Healthcare Diagnostics GmbH Molecular markers for tumor cell content in tissue samples
WO2009038090A1 (ja) 2007-09-19 2009-03-26 Suntory Holdings Limited セサミン類とアラキドン酸類を含有する組成物
CA2702180A1 (en) 2007-10-12 2009-04-16 Peter Humphries Method for opening tight junctions
WO2009102367A2 (en) 2007-11-19 2009-08-20 The Regents Of The University Of Colorado Tight junction protein modulators and uses thereof
WO2009148593A1 (en) 2008-06-02 2009-12-10 Nsabp Foundation, Inc. Identification and use of prognostic and predictive markers in cancer treatment
WO2010046889A1 (en) 2008-10-23 2010-04-29 Quark Pharmaceuticals, Inc. Methods for delivery of sirna to bone marrow cells and uses thereof
CN101381524A (zh) 2008-10-24 2009-03-11 南开大学 单层氧化石墨与水溶性高分子增强复合材料
GB0904957D0 (en) 2009-03-23 2009-05-06 Univ Erasmus Medical Ct Tumour gene profile
WO2010120526A2 (en) 2009-03-31 2010-10-21 Emory University Methods and systems for screening for and diagnosing dna methylation associated with autism spectrum disorders
CN101584860A (zh) 2009-04-27 2009-11-25 西安杰诺瓦生物科技有限公司 重组人Claudin18.2肿瘤疫苗及其制备方法
WO2010141093A2 (en) 2009-06-04 2010-12-09 The University Of Maryland, Baltimore Co-signaling methods for treating cancers
AU2010302955A1 (en) 2009-10-01 2012-05-17 Chipdx Llc System and method for classification of patients
CA2782620A1 (en) 2009-12-01 2011-06-09 Compendia Bioscience, Inc. Classification of cancers
EP2366709A1 (en) 2010-03-16 2011-09-21 BioNTech AG Tumor vaccination involving a humoral immune response against self-proteins
CA2786940C (en) 2010-03-16 2019-09-24 Biontech Ag Tumor vaccination involving a humoral immune response, and proteins therefor including all or a portion of a hepatitis b virus core antigen protein and an epitope of claudin 18.2
US8945847B2 (en) 2010-05-24 2015-02-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods and kits for ascertaining biosafety of an agent
EP2576824A2 (en) 2010-06-07 2013-04-10 Roche Diagnostics GmbH Gene expression markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment
US8454385B2 (en) 2010-06-22 2013-06-04 John Mezzalingua Associates, LLC Coaxial cable connector with strain relief clamp
US20130157891A1 (en) 2010-06-24 2013-06-20 Xiao-Jun Li Organ specific diagnostic panels and methods for identification of organ specific panel proteins
WO2012070014A2 (en) 2010-11-26 2012-05-31 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Identification of novel cell surface markers for pancreatic progenitor cells and definite endodermal cells
CN103119180A (zh) 2011-01-12 2013-05-22 森永乳业株式会社 产生具有免疫调节作用的乳的食物的筛选方法
DE102011005235B4 (de) 2011-03-08 2017-05-24 Sirs-Lab Gmbh Verfahren zum Identifizieren einer Teilmenge von Polynucleotiden aus einer dem Humangenom entsprechenden Ausgangsmenge von Polynucleotiden zur in vitro Bestimmung eines Schweregrads der Wirtsantwort eines Patienten
DE18200782T1 (de) 2012-04-02 2021-10-21 Modernatx, Inc. Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
WO2013174403A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2013174404A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014025198A2 (ko) 2012-08-09 2014-02-13 주식회사 한독 Lfa3 변이체 및 상기 변이체 또는 lfa3 cd2 결합영역과 이에 표적 특이적 폴리펩타이드가 연결된 융합단백질 및 그 용도
WO2014025199A2 (ko) 2012-08-09 2014-02-13 주식회사 한독 스테필로코칼 엔테로톡신 유래의 초항원 변이체 및 이에 표적 특이적 폴리펩타이드가 연결된 융합단백질 및 그 용도
WO2014031859A2 (en) 2012-08-24 2014-02-27 University Of Utah Research Foundation Compositions and methods relating to blood-based biomarkers of breast cancer
US20140073524A1 (en) 2012-09-07 2014-03-13 Institute For Systems Biology Markers and methods for detecting posttraumatic stress disorder (ptsd)
US9856532B2 (en) 2012-09-07 2018-01-02 Institute For Systems Biology Markers and methods for detecting posttraumatic stress disorder (PTSD)

Also Published As

Publication number Publication date
US10017564B2 (en) 2018-07-10
SI3421498T1 (sl) 2022-04-29
EP1948693B1 (en) 2013-03-20
EP2311877A3 (en) 2011-05-18
HK1119721A1 (en) 2009-03-13
HRP20130451T1 (en) 2013-06-30
SG10201405134WA (en) 2014-10-30
DK2311879T3 (da) 2017-09-11
KR20200039015A (ko) 2020-04-14
ES2407819T3 (es) 2013-06-14
HRP20181565T1 (hr) 2018-12-14
CY1124965T1 (el) 2023-01-05
EP3421498B1 (en) 2022-01-05
LT3656793T (lt) 2022-03-10
EP3312197B1 (en) 2019-10-16
EP2311878B1 (en) 2015-10-07
RS52790B (sr) 2013-10-31
ES3036370T3 (en) 2025-09-18
LT2325210T (lt) 2018-11-12
AU2006316767B8 (en) 2012-05-24
DK3421498T3 (da) 2022-02-14
HUE034777T2 (en) 2018-02-28
PT2325210T (pt) 2018-11-07
HUE025900T2 (en) 2016-05-30
PT2311879T (pt) 2017-09-11
US10174104B2 (en) 2019-01-08
RS62947B1 (sr) 2022-03-31
KR101797188B1 (ko) 2017-11-13
EP3421498A1 (en) 2019-01-02
SI2311877T1 (sl) 2015-12-31
US20150252104A1 (en) 2015-09-10
HK1246320A1 (en) 2018-09-07
KR20140106732A (ko) 2014-09-03
SI3656793T1 (sl) 2022-04-29
SI2325210T1 (sl) 2018-11-30
MX339682B (es) 2016-06-06
BRPI0618920A2 (pt) 2011-09-27
PT3421498T (pt) 2022-01-19
PL3656793T3 (pl) 2022-03-28
AU2006316767B9 (en) 2014-02-13
RU2445319C2 (ru) 2012-03-20
SI3312197T1 (sl) 2019-12-31
CA2628126C (en) 2015-06-16
KR20080090403A (ko) 2008-10-08
CA3058722C (en) 2023-05-09
RS54376B1 (sr) 2016-04-28
RU2008125324A (ru) 2009-12-27
MX377450B (es) 2025-03-10
EP2311878A3 (en) 2011-05-18
KR20180126091A (ko) 2018-11-26
SI2311879T1 (sl) 2017-10-30
HUE025578T2 (en) 2016-04-28
CY1121002T1 (el) 2019-12-11
HUE058777T2 (hu) 2022-09-28
CY1114050T1 (el) 2016-07-27
HRP20151257T1 (hr) 2016-01-15
EP4112645B1 (en) 2025-06-18
HUE058814T2 (hu) 2022-09-28
EP2311879A2 (en) 2011-04-20
AU2006316767A1 (en) 2007-05-31
US9499609B2 (en) 2016-11-22
KR101535292B1 (ko) 2015-07-09
PT2311878E (pt) 2016-01-26
KR101463585B1 (ko) 2014-11-21
US20180127489A1 (en) 2018-05-10
CN103509110A (zh) 2014-01-15
HUE041538T2 (hu) 2019-05-28
CA2886580C (en) 2019-12-10
PL2311877T3 (pl) 2016-01-29
HRP20220246T3 (hr) 2022-04-29
MX2020011789A (es) 2020-11-24
LT3421498T (lt) 2022-03-10
HRP20151136T1 (hr) 2016-01-01
EP2311879A3 (en) 2011-05-18
EP2325210B1 (en) 2018-09-05
PT1948693E (pt) 2013-06-05
KR101669631B1 (ko) 2016-10-26
PL3312197T3 (pl) 2020-03-31
KR102099875B1 (ko) 2020-04-10
DK2325210T3 (da) 2018-10-29
HRP20171337T1 (hr) 2017-11-03
EP3656793A1 (en) 2020-05-27
RS59563B1 (sr) 2019-12-31
PL1948693T3 (pl) 2013-08-30
KR20170125131A (ko) 2017-11-13
CN101312989A (zh) 2008-11-26
CN103509114B (zh) 2018-06-29
CA2886580A1 (en) 2007-05-31
CY1125027T1 (el) 2023-06-09
DK3312197T3 (da) 2019-11-11
SI2311878T1 (sl) 2016-01-29
JP6086894B2 (ja) 2017-03-01
US20120164160A1 (en) 2012-06-28
MX2020011792A (es) 2020-12-07
PL3421498T3 (pl) 2022-02-28
PT2311877E (pt) 2015-11-18
DK2311878T3 (da) 2016-01-04
CA2628126A1 (en) 2007-05-31
CN101312989B (zh) 2013-08-07
EP2311879B1 (en) 2017-06-21
RS57781B1 (sr) 2018-12-31
EP2311878A2 (en) 2011-04-20
AU2006316767B2 (en) 2012-02-02
US20090169547A1 (en) 2009-07-02
CY1116964T1 (el) 2017-04-05
LT2311879T (lt) 2017-09-25
ES2642688T3 (es) 2017-11-17
EP2311877B1 (en) 2015-08-26
EP3656793B1 (en) 2022-02-02
HK1151305A1 (en) 2012-01-27
CN103509114A (zh) 2014-01-15
JP2016196467A (ja) 2016-11-24
US20150252103A1 (en) 2015-09-10
HRP20220155T3 (hr) 2022-04-15
ES2905951T3 (es) 2022-04-12
JP5933157B2 (ja) 2016-06-08
US20120195830A1 (en) 2012-08-02
ES2757498T3 (es) 2020-04-29
KR20160081988A (ko) 2016-07-08
EP2295469A2 (en) 2011-03-16
EP2311877A2 (en) 2011-04-20
HK1151535A1 (en) 2012-02-03
PL2311879T3 (pl) 2018-03-30
JP2013079241A (ja) 2013-05-02
US20240117022A1 (en) 2024-04-11
US8168427B2 (en) 2012-05-01
JP2009517354A (ja) 2009-04-30
ES2907716T3 (es) 2022-04-26
EP2325210A1 (en) 2011-05-25
KR101921287B1 (ko) 2018-11-22
US20160185860A1 (en) 2016-06-30
EP4112645A1 (en) 2023-01-04
RS62886B1 (sr) 2022-03-31
PL2325210T3 (pl) 2018-12-31
CY1117031T1 (el) 2017-04-05
SG10201903351SA (en) 2019-05-30
PL2311878T3 (pl) 2016-02-29
HRP20191968T1 (hr) 2020-01-24
CY1119290T1 (el) 2018-02-14
EP3312197A1 (en) 2018-04-25
BRPI0618920A8 (pt) 2022-11-22
SI1948693T1 (sl) 2013-07-31
CN103509110B (zh) 2015-12-09
US10738108B2 (en) 2020-08-11
EP1790664A1 (en) 2007-05-30
PT3312197T (pt) 2019-11-26
EP2295469A3 (en) 2011-05-18
US11739139B2 (en) 2023-08-29
BRPI0618920B8 (pt) 2023-02-28
ES2689746T3 (es) 2018-11-15
HUE048404T2 (hu) 2020-07-28
ES2550027T3 (es) 2015-11-04
ME03608B (me) 2020-07-20
CY1122346T1 (el) 2021-01-27
JP6085148B2 (ja) 2017-02-22
EP1948693A1 (en) 2008-07-30
PT3656793T (pt) 2022-03-08
BRPI0618920B1 (pt) 2022-12-13
KR20140018386A (ko) 2014-02-12
US20200385448A1 (en) 2020-12-10
ES2555979T3 (es) 2016-01-12
JP6261650B2 (ja) 2018-01-17
CA3058722A1 (en) 2007-05-31
US9212228B2 (en) 2015-12-15
LT3312197T (lt) 2019-11-11
DK1948693T3 (da) 2013-06-10
US9751934B2 (en) 2017-09-05
RS56327B1 (sr) 2017-12-29
JP2015083579A (ja) 2015-04-30
HK1257914A1 (en) 2019-11-01
RS54468B1 (sr) 2016-06-30
WO2007059997A1 (en) 2007-05-31
DK2311877T3 (da) 2015-11-16

Similar Documents

Publication Publication Date Title
DK3656793T3 (da) Monoklonale antistoffer mod claudin-18 til cancerbehandling
DK3401334T3 (da) Monoklonale antistoffer mod claudin-18 til cancerbehandling
IL284991A (en) Antibodies against cd38 for treatment of multiple myeloma
IL197217B (en) Novel anti-cd38 antibodies for the treatment of cancer
CY2016030I1 (el) Αντισωματα εναντι της il-17
HRP20180485T1 (hr) Monoklonska antitijela za gt468 za liječenje raka
DK1866338T3 (da) Antistoffer mod cd38 til behandling af myelomatose